‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its Dividend
Jim Cramer declined to recommend Pfizer (PFE) despite its 7% dividend, citing lack of growth prospects. Pfizer's Q2 2026 revenue was $15.0B, beating estimates, but net income fell. Cramer noted challenges from patent cliffs and COVID vaccine declines. Analysts now rate PFE a 'Buy' with an average target of $28.61.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift provide a fresh catalyst for price movement, but lingering growth concerns may temper enthusiasm.
Market read
Pfizer’s earnings and guidance update are material for dividend‑focused and growth investors, potentially moving the stock and influencing sector sentiment.
What to watch
Potential impact of upcoming Metsera and Innovent collaborations and the $4.3 bn impairment could weigh on future earnings.
Background
Jim Cramer discussed Pfizer’s dividend yield versus growth prospects on Mad Money, while the company released its Q2 2026 earnings and raised guidance.
Ticker impact
Pfizer reported Q2 2026 revenue of $15.0 bn beating estimates, raised full‑year revenue guidance to $61.5 bn and reaffirmed EPS $2.80‑$3.00, while analyst consensus upgraded to Buy.
Potential upside of 5‑10% over the next week if the market digests the guidance lift.
Large‑cap earnings beat with guidance raise is material; however, growth concerns and dividend‑only appeal limit the upside.
Market effects
Highlights ongoing challenges in the pharma sector with patent cliffs and pricing pressures, but also shows that large‑cap peers can still raise guidance.
U.S. healthcare stocks may see modest buying pressure as investors reassess dividend‑yielding names.
Pfizer's earnings influence global biotech sentiment, especially regarding COVID‑19 product declines.
Counterpoint
Cramer’s refusal to recommend despite the earnings beat suggests that growth catalysts remain insufficient, warning against over‑optimism.
Key entities
- companyPfizer
Large‑cap pharmaceutical company reporting Q2 2026 results.
- personJim Cramer
Host of Mad Money who expressed a negative recommendation.
